COMP <GO>

RDY vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY

Dr. Reddy's Laboratories Ltd (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: RDY 2 — LLY 13

▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY

LAST: $14.17 (+0.43%) • MKT CAP: $11.78B

balance-sheet

3.74

LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T

balance-sheet

9.29

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RDY VS. LLY) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	RDY	LLY	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	41.00%	83.64%	-42.64	LLY	/gross-margins <GO>
Return on Invested Capital (ROIC)	9.90%	32.36%	-22.46	LLY	/roic <GO>
EV/EBITDA & P/E Valuation	21.0x	36.4x	-15.42	RDY	/valuation <GO>
Free Cash Flow Yield	2.21%	2.30%	-0.09	LLY	/fcf-yield <GO>
Operating Margin	13.90%	40.21%	-26.31	LLY	/operating-margins <GO>
Net Profit Margin	10.90%	31.90%	-21.00	LLY	/net-margins <GO>
Revenue Growth (YoY)	6.60%	45.51%	-38.91	LLY	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.49%	-0.49	LLY	/dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE	3.74	9.29	-5.55	LLY	/balance-sheet <GO>
Piotroski F-Score Quality	8/9	9/9	-1.00	LLY	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	7.10%	6.77%	+0.33	LLY	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	77.7	77.9	-0.20	LLY	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	1.05	0.51	+0.54	RDY	/macro-sensitivity <GO>
Forward P/E Multiple	30.5x	26.3x	+4.25	LLY	/forward-pe <GO>
Enterprise Scale & Market Cap	$11.78B	$1.33T	-$1.32T	LLY	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	RDY REV	LLY REV	RDY GROSS %	LLY GROSS %	RDY FCF	LLY FCF
FY 2025	—	$65.18B	—	83.0%	—	$16.81B
FY 2024	—	$45.04B	—	81.3%	—	$8.82B
FY 2023	—	$34.12B	—	79.3%	—	$4.24B
FY 2022	—	$28.54B	—	76.8%	—	$7.59B
FY 2021	—	$28.32B	—	74.2%	—	$7.37B

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

RDY // BETA 1.05

LLY // BETA 0.51